Treatment of syngeneic mice bearing synchronous Neuro2a tumors with CpG-coated Prussian blue nanoparticles-based photothermal therapy and anti CTLA-4 immunotherapy was characterized by complete tumor regression in both primary and secondary tumors, as well as improved rates of long-term survival compared to controls, and this was dependent on activation of CD4 + and CD8 + T and NK cells [204]. The gene discussed is CTLA4; the disease is neoplasm.